Calliditas Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Renee Aguiar-Lucander

Algemeen directeur

SEK 18.4m

Totale compensatie

Percentage CEO-salaris	36.6%
Dienstverband CEO	7.4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Renee Aguiar-Lucander's beloning veranderd ten opzichte van Calliditas Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 480m
Mar 31 2024	n/a	n/a	-SEK 525m
Dec 31 2023	SEK 18m	SEK 7m	-SEK 466m
Sep 30 2023	n/a	n/a	-SEK 451m
Jun 30 2023	n/a	n/a	-SEK 292m
Mar 31 2023	n/a	n/a	-SEK 393m
Dec 31 2022	SEK 13m	SEK 6m	-SEK 412m
Sep 30 2022	n/a	n/a	-SEK 628m
Jun 30 2022	n/a	n/a	-SEK 608m
Mar 31 2022	n/a	n/a	-SEK 576m
Dec 31 2021	SEK 11m	SEK 5m	-SEK 500m
Sep 30 2021	n/a	n/a	-SEK 452m
Jun 30 2021	n/a	n/a	-SEK 600m
Mar 31 2021	n/a	n/a	-SEK 501m
Dec 31 2020	SEK 7m	SEK 3m	-SEK 433m
Sep 30 2020	n/a	n/a	-SEK 286m
Jun 30 2020	n/a	n/a	-SEK 198m
Mar 31 2020	n/a	n/a	-SEK 54m
Dec 31 2019	SEK 4m	SEK 3m	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 54m
Jun 30 2019	n/a	n/a	-SEK 35m
Mar 31 2019	n/a	n/a	-SEK 136m
Dec 31 2018	SEK 4m	SEK 2m	-SEK 132m

Compensatie versus markt: De totale vergoeding ($USD 1.77M ) Renee } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.81M ).

Compensatie versus inkomsten: De vergoeding van Renee is gestegen terwijl het bedrijf verliesgevend is.

CEO

Renee Aguiar-Lucander (62 yo)

7.4yrs

Tenure

SEK 18,367,000

Compensatie

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Renee Aguiar-Lucander	Chief Executive Officer	7.4yrs	SEK 18.37m	geen gegevens
Fredrik Johansson	Chief Financial Officer	7.2yrs	geen gegevens	0% € 0
Lars Stubberud	Vice President of Technical Operations	1.8yrs	geen gegevens	geen gegevens
Asa Hillsten	Head of IR & Sustainability	1.8yrs	geen gegevens	geen gegevens
Brian Gorman	Group General Counsel	1.8yrs	geen gegevens	geen gegevens
Sandra Frithiof	Vice President of Human Resources	4.8yrs	geen gegevens	geen gegevens
Ann-Kristin Myde	Head of Clinical Development & VP of Project Management	7.8yrs	geen gegevens	geen gegevens
Richard Philipson	Chief Medical Officer	4.3yrs	geen gegevens	geen gegevens
Teona Johnson	Head of US Marketing	3.6yrs	geen gegevens	geen gegevens
David Ferraro	Head of US Sales	3.6yrs	geen gegevens	geen gegevens
Monika Tornsen	President of North America	less than a year	geen gegevens	geen gegevens
Christopher Ngai	Vice President of Market Access	no data	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LC8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yoshikazu Aoki	Non-Executive Director	less than a year	geen gegevens	geen gegevens
Mark Hensley	Chairman	less than a year	geen gegevens	geen gegevens
Jonathan Barratt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jürgen Floege	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Richard Lafayette	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Brad Rovin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Vladimir Tesar	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Hérnan Trimarchi	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Masaya Etoh	Non-Executive Director	less than a year	geen gegevens	geen gegevens
Heather Reich	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Hong Zhang	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

0.08yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van LC8 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.1 jaar), wat duidt op een nieuw bestuur.

Calliditas Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Calliditas Therapeutics AB (publ) Announces Board Changes

Chief Medical Officer recently sold €917k worth of stock

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Independent Chairman recently bought €92k worth of stock

Calliditas Therapeutics AB (publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Recent updates

Calliditas Therapeutics AB (publ) Announces Board Changes

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Second quarter 2024 earnings released: kr0.88 loss per share (vs kr1.71 loss in 2Q 2023)

Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo

Calliditas Therapeutics AB Announces Positive Transform Phase 2b Topline Data in Primary Biliary Cholangitis

Chief Medical Officer recently sold €917k worth of stock

Calliditas Therapeutics AB (publ) Provides Setanaxib Patent Update

Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and others shareholders for SEK 11.2 billion.

New major risk - Share price stability

Calliditas Therapeutics AB (Publ) Reaffirms Earnings Guidance for the Year Ending December 31, 2024

Forecast breakeven date pushed back to 2025

Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib

Full year 2023 earnings released: kr8.69 loss per share (vs kr7.78 loss in FY 2022)

Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO

Full year 2023 earnings released: kr8.69 loss per share (vs kr7.78 loss in FY 2022)

Calliditas Therapeutics AB Provides Patent Update

Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023

Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO

Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO

Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome

Third quarter 2023 earnings released: kr3.14 loss per share (vs kr0.17 loss in 3Q 2022)

Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

New major risk - Share price stability

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023

STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization

Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy

Second quarter 2023 earnings released: kr1.71 loss per share (vs kr3.62 loss in 2Q 2022)

Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib

Independent Chairman recently bought €92k worth of stock

Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Calliditas Therapeutics AB (publ) Announces Board Changes

Forecast breakeven date pushed back to 2024

Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023

No longer forecast to breakeven

Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023

Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023

Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy

Calliditas Therapeutics AB Announces Executive Appointments

Calliditas Therapeutics AB (Publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces First Patient Randomized in Phase 2 Trial in Head and Neck Cancer

Calliditas Therapeutics AB Launches an Online Patient Platform

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur